ClinicaliQ Trial Snapshot
- Early Detection and IntervenTion in Heart Failure — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07731490.
- What is being tested: Early detection and intervention strategies in heart failure to identify patients before symptomatic disease develops and prevent progression of cardiac dysfunction.
- Patient eligibility overview: The trial targets individuals at risk of developing heart failure, including those with hypertension, diabetes, obesity, or previous cardiac events, with particular focus on asymptomatic or early-stage disease.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood…
Eligibility Snapshot
- : * General consent (GC) has not been rejected. * Age ≥ 65 years. * Elective percutaneous coronary intervention* (PCI), pulmonary vein isolation* (PVI), pacemaker implantation* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention* (TAVI), major non-cardiac surgery* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h). *
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.